Macugen Eyetech / Pfizer Inc - Treatment for Neovascular (Wet) Age-Related Macular Degeneration

Macugen is a selective vascular endothelial growth factor (VEGF) antagonist indicated for the treatment of neovascular (wet) age-related macular degeneration (AMD), an eye disease associated with aging that destroys central vision.

Posted: December 2004

Related Articles:

Macugen (pegaptanib) FDA Approval History

View comments

Hide
(web3)